Skip to main content

United Therapeutics Corporation (UTHR)

NASDAQ: UTHR · IEX Real-Time Price · USD
187.07 -0.53 (-0.28%)
Oct 15, 2021 4:00 PM EDT - Market closed
Market Cap8.40B
Revenue (ttm)1.59B
Net Income (ttm)470.90M
Shares Out44.80M
EPS (ttm)10.25
PE Ratio18.25
Forward PE11.38
Dividendn/a
Ex-Dividend Daten/a
Volume341,402
Open187.93
Previous Close187.60
Day's Range184.31 - 188.30
52-Week Range114.18 - 216.90
Beta0.55
AnalystsBuy
Price Target231.89 (+24.0%)
Est. Earnings DateNov 3, 2021

About UTHR

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostini...

IndustryBiotechnology
IPO DateJun 17, 1999
CEOMartine Rothblatt
Employees950
Stock ExchangeNASDAQ
Ticker SymbolUTHR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for UTHR stock is "Buy." The 12-month stock price forecast is 231.89, which is an increase of 23.96% from the latest price.

Price Target
$231.89
(23.96% upside)
Analyst Consensus: Buy

News

United Therapeutics to Present New Data at CHEST Annual Meeting 2021

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.

6 days ago - PRNewsWire

7 Top-Rated Pharmaceutical Stocks To Invest in for October

It's a great time to look beyond the big name pharmaceutical stocks and look for great niche players with big futures. The post 7 Top-Rated Pharmaceutical Stocks To Invest in for October appeared first ...

Other symbols:CLSDINVAMTEXORMPVERU
1 week ago - InvestorPlace

United Therapeutics Converts to a Public Benefit Corporation Following Shareholder Approval

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.

2 weeks ago - PRNewsWire

United Therapeutics Releases its Annual Corporate Responsibility Report

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.

1 month ago - PRNewsWire

United Therapeutics-MannKind's Formulated Tyvaso Shows Benefit In Pulmonary Hypertension Patients

United Therapeutics Corporation (NASDAQ: UTHR) has presented new clinical data from the BREEZE study evaluating Tyvaso DPI (treprostinil) in patients with pulmonary arterial hypertension (PAH). Related ...

Other symbols:MNKD
1 month ago - Benzinga

United Therapeutics (UTHR) Up 3.4% Since Last Earnings Report: Can It Continue?

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?

Other symbols:UAL
1 month ago - Zacks Investment Research

Here's Why United Therapeutics Stock May Continue To Trend Higher

The stock price of United Therapeutics, a biotechnology company, has seen a rise of over 15% over the last twenty-one trading days, and it is up a solid 97% over the last twelve-month period. The rally ...

1 month ago - Forbes

United Therapeutics (UTHR) Q2 Earnings & Sales Beat, Stock Up

United Therapeutics (UTHR) second-quarter earnings and sales beat estimates. Higher sales of Orenitram, Unituxin and Tyvaso mainly drive the top line in the quarter.

2 months ago - Zacks Investment Research

Why United Therapeutics Blasted 14% Higher Today

Every one of the company's products booked a revenue gain in Q2.

2 months ago - The Motley Fool

United Therapeutics (UTHR) Q2 Earnings and Revenues Surpass Estimates

United Therapeutics (UTHR) delivered earnings and revenue surprises of 27.62% and 17.66%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

United Therapeutics: Q2 Earnings Insights

Shares of United Therapeutics (NASDAQ:UTHR) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share increased 11.14% over the past year to $4.09, which beat the e...

2 months ago - Benzinga

United Therapeutics Corporation Reports Second Quarter 2021 Financial Results

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.

2 months ago - PRNewsWire

United Therapeutics Corporation To Present At The 2021 Wedbush PacGrow Healthcare Virtual Conference

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.

2 months ago - PRNewsWire

United Therapeutics (UTHR) to Report Q2 Results: Wall Street Expects Earnings Growth

United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

3 LGBTQ+ CEOs Leading Your Investment Portfolio

Pride Month is a good time to be proud of these pioneering corporate leaders.

Other symbols:AAPLM
3 months ago - The Motley Fool

United Therapeutics (UTHR) Tyvaso DPI Gets FDA's Priority Tag

United Therapeutics' (UTHR) Tyvaso DPI is a drug device combination therapy, comprising the dry powder formulation of Tyvaso and a small, portable, dry powder inhaler.

4 months ago - Zacks Investment Research

MannKind And United Therapeutics Achieve A Major Milestone In The Development Of Tyvaso DPI™ With New Drug Applicatio...

DANBURY, Conn., June 16, 2021 /PRNewswire/ -- MannKind Corporation (Nasdaq: MNKD) and United Therapeutics Corporation (Nasdaq: UTHR) reached a major milestone today with the announcement that the U.S. F...

Other symbols:MNKD
4 months ago - PRNewsWire

United Therapeutics Announces FDA Acceptance of Tyvaso DPI™ New Drug Application For Priority Review

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.

4 months ago - PRNewsWire

United Therapeutics Pursues New Claims For Trade Secret Misappropriation Against Liquidia

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.

4 months ago - PRNewsWire

Why Is United Therapeutics (UTHR) Down 8.8% Since Last Earnings Report?

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?

Other symbols:UAL
4 months ago - Zacks Investment Research